Findings Over 10 years, haemoglobin A,, (HbA,,) was 7.0% (6.2-8.2) in the intensive group compared with 7.9% (6.9-8.8) in the conventional group-an 11% reduction. There was no difference in HM,, among agents in the intensive group. Compared with the conventional group, the risk in the intensive group was 12% lower (95% Cl 1-21, p=O.O29) for any diabetes-related endpoint; 10% lower (-11 to 27, p=O.34) for any diabetes-related death; and 6% lower (-10 to 20, p=O.44) for all-cause mortality. Most of the risk reduction in the any diabetes-related aggregate endpoint was due to a 25% risk reduction , p=O.O099) in microvascular endpoints, including the need for retinal photocoagulation.
There was no difference for any of the three aggregate endpoints between the three intensive agents (chlorpropamide, glibenclamide, or insulin).
Patients in the intensive group had more hypoglycaemic episodes than those in the conventional group on both types of analysis (both peO.0001). The rates of major hypoglycaemic episodes per year were 0.7% with conventional treatment, 1.0% with chlorpropamide, 1.4% with glibenclamide, and 1.8% with insulin. Weight gain was 2ignificantly higher in the intensive group (mean 2.9 kg) than in the conventional group (p<O.OOl), and patients assigned insulin had a greater gain in weight (4.0 kg) than those assigned chlorpropamide (2.6 kg) or glibenclamide (1.7 kg).
Introduction
Started in 1977, the UK Prospective Diabetes Study (UKPDS) was designed to establish whether, in patients with type 2 diabetes, intensive blood-glucose control reduced the risk of macrovascular or microvascular complications, and whether any particular therapy was advantageous.
Most intervention studies have assessed microvascular disease: improved glucose control has delayed the We report the final results of our study of intensive blood-glucose control policy, with sulphonylurea or insulin therapy, compared with conventional treatment policy with diet, on the risk of microvascular and macrovascular clinical complications. We also investigated whether there was any particular benefit or risk with sulphonylurea or insulin therapy.
Methods
Between 1977 and 1991, general practitioners in the catchment areas of the 23 participating UWDS hospitals were asked to refer all patients with newly diagnosed diabetes aged 25-65 years. Patients generally attended a UKPDS clinic within 2 weeks of referral. Patients who had a fasting plasma glucose (FPG) greater than 6 mmol/L on two mornings, l-3 weeks apart, were eligible for the study. An FPG of 6 mmol/L was selected because this was just above the upper limit of normal for our reference range. The exclusion criteria were: ketonuria more than 3 mmol/L; serum creatinine greater than 175 umol/L; myocardial infarction in the previous year; current angina or heart failure; more than one major vascular event; retinopathy requiring laser treatment; malignant hypertension; uncorrected endocrine disorder; occupation that precluded insulin therapy (eg, driver of heavy goods vehicle); severe concurrent illness that would limit life or require extensive systemic treatment; inadequate understanding; and unwillingness to enter the study. 7616 patients were referred and 5102 were recruited (58% male). The 25 14 patients excluded were similar in age, sex, and glycaemic status to those recruited. The study design and protocol amendments, which conform with the guidelines of the Time from randomisation (years)
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Patients followed for 10 years All patients assigned to regimen To investigate differences among chlorpropamide, insulin, and glibenclamide, four additional clinical-endpoint aggregates were used: myocardial infarction (fatal and non-fatal) and sudden death; stroke (fatal and non-fatal); amputation or death due to peripheral vascular disease; and microvascular complications (retinopathy requiring photocoagulation, vitreous haemorrhage, and or fatal or non-fatal renal failure).
Surrogate endpoints
Subclinical, surrogate variables were assessed every 3 years. The criteria were: for neuropathy-loss of both ankle or both knee reflexes or mean biothesiometer reading from both toes 25 V or greater; for autonomic neuropathy-R-R interval less than the age-adjusted normal range (a ratio c 1.03 of the longest R-R interval at approximately beat 30 to the shortest at approximately beat 15); for orthostatic hypotension-systolic fall of 30 mm Hg or more, or diastolic fall of 10 mm Hg or more;
and for impotence-no ejaculation or erection. Retinopathy was defined as one microaneurysm or more in one eye or worse retinopathy, and progression of retinopathy as a two-step change in grade. Poor visual acuity was: logMAR more than 0.3 (unable to drive a car), more than 0.7 (US definition of blindness), and logMAR 1.0 or greater (WHO definition of blindness). Deterioration of vision was defined as a three-line deterioration in reading an ETDRS chart. Ischaemic heart disease by Minnesota coding was either WHO grade 1 (possible coronary heart disease) or grade 2 (probable coronary heart disease). Left-ventricular hypertrophy was a cardiothoracic ratio 0.5 or greater.
The study closed on Sept 30, 1997. All available information for each endpoint, such as admission notes, operation records, death certificates, and necropsy reports, were gathered. The file, with no reference to assigned or actual therapy, was reviewed independently by two physicians who assigned appropriate International Classification of Disease-9 codeszo Any disagreements between the two assessors were discussed and the evidence reviewed; if agreement was not possible the file was submitted to two different assessors for final arbitration.
Statistical analysis
When the UKPDS started in the late 197Os, it was thought that improved blood-glucose control might reduce the incidence of diabetes-related endpoints by 40%. This seemed reasonable since the risk of cardiovascular events in patients with diabetes is at least twice that of people with normal glucose tolerance and microvascular complications do not occur in the normoglycaemic population. The first three aggregate endpoints were defined and, for death and major cardiovascular events (the stopping criteria), the original power calculation to find a 40% difference between the intensive and conventional groups was a sample size of 3600 with 81% power at the 1% level of significance.
However, by 1987 no risk reduction was seen in any of these aggregates and it became obvious a 40% advantage was unlikely to be obtained. The publication of other intervention studies of chronic diseases in the mid 1980s suggested that a more realistic goal would be a difference of 15%. Accordingly, the study was extended to include randomisation of 3867 patients with a median time from randomisation of 11 years to the end of the study in 1997. In 1992, at the 1% level of significance, the power for any diabetes-related endpoint and for diabetesrelated death was calculated as 81% and 23%, respectively. by the product-limit (Kaplan-Meier) method. Yearly averaged data for weight and FPG were calculated as the median of three consecutive visits for each patient-ie, the annual visit, and the 3 month visit before and after this. HbA,, data were from the annual assessment but overall values for HbA,, during a period were the median for each patient for each allocation. Glucose control and HbA,, were assessed both cross-sectionally and in the cohort with 10 years' follow-up.
Urine albumin was assessed in mg/L with no adjustment for urine creatinine concentration.2' Data for albuminuria at the triennial visit were the median of that year and the years before and after. Hypoglycaemic episodes in each year were analysed both by intention to treat and by actual therapy.
Safety
The The median follow-up for endpoint analyses was 10.0 years (IQR 7.7-12.4).
The median follow-up for the comparison of conventional treatment with each of the three intensive agents was 11.1 years (9*0-13-O). The percentage of total person-years for which the assigned or other therapies were taken in the conventional or intensive groups are shown in table 3.
At the end of the trial, the vital status of 76 (2.0%) patients who had emigrated was not known; 57 and 19 in intensive and conventional groups, respectively, which reflects the 70/30 randomisation. A further 91 (2.4%) patients (65 in the intensive group) could not be contacted in the last year of the study for assessment of clinical endpoints. The corresponding numbers for comparison of the individual intensive agents were 69 (2.7%) emigrated and 63 (2.1%) not contactable.
In the conventional group, the FPG and HbA,, increased steadily over 10 years from randomisation in both the cohort study of 461 patients and in the cross-sectional data at each year (figure 2). In the intensive group, there was an initial decrease in FPG and HbA,, in the first year, both in the 10 year cohort of 1180 patients and in the cross-sectional data, with a subsequent increase similar to that in the conventional Years from randomisation and 8.4% (7.2-9.4) for the second, and 8.1% (7.0-g-4) and 8.7% (7.5-9.7) for the third period (all p<O.OOOl) .
The median HbA,, values over 10 years with chlorpropamide (6.7%), glibenclamide (7.2%), and insulin (7.1%) were each significantly lower than that with conventional treatment (7*9%, p<O.OOOl). HbA,, was significantly lower in the chlorpropamide group than in the glibenclamide group (p=O*OO8) but neither differed from the insulin group (figure 3).
There was a significant increase in weight in the intensive group compared with the conventional group, by (mean) 3.1 kg (99% CI -0.9 to 7.0, p<O*OOOl) for the cohort at 10 years (figure 2). Patients assigned either of the sulphonylureas gained more weight than the conventional group, whereas patients assigned insulin gained more weight than those assigned a sulphonylurea (figure 3). In the cohort at 10 years, those assigned chlorpropamide gained 2.6 kg more (1.6-3.6, p<O.OO 1); those assigned glibenclamide gained 1.7 kg more (0.7-2.7, p<O*OOl); and those assigned insulin gained 4.0 kg more (3.1-4.9, p<O.OOOl) than those assigned conventional therapy ( figure 3) . The cross-sectional data were similar to the cohort data.
Median fasting plasma insulin increased in the intensive group, and was 17.9 pmol/L (95% CI 0.5-35.3) greater than in the conventional group over the first 10 years (p<O.OOOl, figure 2). Fasting plasma insulin in participants assigned to sulphonylureas increased more than in those in the conventional group over the first 3 years, and in those assigned to insulin this increase was even greater from 6 years as higher insulin doses were given (figure 3).
The median insulin doses at 3 years, 6 years, 9 years, other allocations (p<O.OOl). The proportion of patients on therapy for hypertension was higher among those and 12 years in patients assigned intensive treatment with insulin were 22 U (IQR 14-34), 28 U (18-45), 34 U (20~50), and 36 U (23~53), respectively. Median doses of insulin for patients with body-mass indices less than 25 kg/m* and greater than 35 kg/m* were 16 U (10-24) and 36 U (23-50) at 3 years; the corresponding doses were 24 U (14-36) and 60 U (40-82) at 12 years. The maximum insulin dose was 400 U per day.
Systolic and diastolic blood pressure were significantly higher throughout the study in patients assigned chlorpropamide than in those assigned any of the other therapies. For example, at 6 years' follow-up the mean blood pressure in the chlorpropamide group was 143/82 mm Hg compared with 138/80 mm Hg in each of the 14.0 years in the intensive group compared with 12.7 years in the conventional group (pzO.029).
Aggregate and single endpoints
The number of patients who developed aggregate or single clinical endpoints in the intensive and conventional groups are shown in figure 4 ; similarly, figure 5 shows the comparison between the three intensive groups and conventional treatment. Kaplan-Meier plots for any diabetes-related endpointie, the complication-free interval-and diabetes-related deaths are shown in figure 6 and those for microvascular endpoints, myocardial infarction, and stroke in figure 7 .
The number needed to treat to prevent one patient developing any of the single endpoints over 10 years was 19.6 patients (95% CI 10-500). The complication-free interval, expressed as the follow-up to when 50% of the patients had at least one diabetes-related endpoint, was assigned chlorpropamide (43%) than among those assigned conventional treatment, glibenclamide, or insulin (34%, 36%, and 38%, respectively; ~~0.022). There was no significant difference between the three intensive treatments on microvascular endpoints or the risk reduction for retinal photocoagulation (figure 5). Few patients developed renal failure, died from renal disease, or had vitreous haemorrhage. Figure 8 shows the proportion of patients with surrogate endpoints (two-step progression of retinopathy, biothesiometer threshold, microalbuminuria, proteinuria, and two-fold increase in plasma creatinine) found at 3-year visits. After 6 years' follow-up, a smaller proportion of patients in the intensive group than in the conventional group had a two-step deterioration in retinopathy:
Surrogate endpoints
this finding was significant even when retinal photocoagulation was excluded (data not shown). When the three intensive treatments were compared, patients assigned chlorpropamide did not have the same risk reduction as those assigned glibenclamide or insulin (p=O*OO56) for the progression of retinopathy at 12 years' follow-up, and adjustment for the difference in mean systolic or diastolic blood pressure by logistic regression analysis did not change this finding.
There was no difference between conventional and intensive treatments in the deterioration of visual acuity with a mean ETDRS chart reduction of one letter per 3 years in each group. At 12 years the proportion of patients blind in both eyes (logMAR>0. 7) did not differ between the intensive and conventional groups (6/734 [O-8%]) z)s 5/263 [1.9%], p=Oe15). 11% of patients in both groups did not have adequate vision for a driving licence (logMAR > 0.3 in both eyes).
Proportions of patients with absent ankle reflexes did not differ between intensive and conventional groups (35 zx 37%, p=O*60); similar proportions had absent knee reflexes (11 vs 12%, ~~0.42).
The heart-rate responses to deep breathing and standing did not differ between the intensive and conventional groups, but at 12 years the basal heart rate &as significantly lower in the intensive than in the conventional group (median 69.8 [IQR 62.5-78.91 vs 74.4 [65.2-83.31 bpm, p<O.OOl). P-blockers were taken by 16% and 19% (~~0.58) of patients in the intensive and conventional groups.
The proportion of patients with impotence did not differ at 12 years in the intensive and conventional groups (46.8 'us 54.7%, respectively; p=O*O9).
There was no difference between the intensive and conventional treatment groups, or between the three intensive allocations, in the proportion of patients who had a silent myocardial infarction, cardiomegaly, evidence of peripheral vascular disease by doppler blood pressure, or absent peripheral pulses.
Hyperglycaemia and hypoglycaemia
The proportion of patients with one or more major, or any, hypoglycaemic episode in a year was significantly higher in the intensive group than in the conventional group (figure 9). When the three intensive treatments were compared by actual therapy, major hypoglycaemic episodes or any episode were most common in patients on insulin therapy (figure 10). During the first few years of therapy, any hypoglycaemic episodes were also frequent in patients on glibenclamide or chlorpropamide, but fell as FPG increased. By intention-to-treat analysis, there was less difference between the allocations as more patients in the conventional group had sulphonylurea or insulin therapy added. One insulin-group patient died at home, unattended: this death was attributed to hypoglycaemia. In the conventional group, one patient died from hyperglycaemic, coma after a febrile illness.
Over the first 10 years, the mean proportion . of patients per year with one or more major hypoglycaemic episodes while taking their assigned intensive or conventional treatment was 0.4% for chlorpropamide, 0.6% for glibenclamide, 2.3% for insulin, and 0.1% for diet; the corresponding rates for any hypoglycaemic episode were ll.O%, 17.7%, 36+%, and 1.2%.
By intention-to-treat analyses, major hypoglycaemic episodes occurred with chlorpropamide (1 *O%), glibenclamide (1*4%), insulin (1+3%), and diet (0.7%) and any hypoglycaemic episodes in 16%, 21%, 28%, and 1 O%, respectively. Hypoglycaemic episodes in patients on diet therapy were reactive and occurred either after meals or after termination of glucose infusions given while in hospital (eg, postoperatively).
Discussion
We found that an intensive blood-glucose-control policy with an 11% reduction in median HbA,, over the first 10 years decreased the frequency of some clinical complications of type 2 diabetes. The intensive treatment group had a substantial, 25% reduction in the risk of microvascular endpoints, most of which was due to fewer patients requiring photocoagulation.
There was evidence, albeit inconclusive, of a 16% risk reduction (p=O*O52) for myocardial infarction, which included non-fatal and fatal myocardial infarction and sudden death, but diabetes-related mortality and allcause mortality did not differ between the intensive and conventional groups. The study did not have sufficient power to exclude a beneficial effect on fatal outcomes. The progression of subclinical, surrogate variables of microvascular disease was also decreased, in agreement with other studies of improved glucose control.'-' The median complication-free interval was 1.3 years longer in the intensive group.
The UGDP raised concerns that the sulphonylurea, tolbutamide, may increase the risk of cardiovascular death, and several mechanisms by which sulphonylureas might have an adverse effect were suggested. However, we found no difference in the rates of myocardial infarction or diabetes-related death between participants assigned sulphonylurea or insulin therapies. Studies in animals suggested that first-generation sulphonylureas, such as chlorpropamide, might increase the risk of ventricular fibrillation,'0 but this suggestion was not supported by our findings since the rate of sudden death was similar in the groups assigned chlorpropamide, glibenclamide, or insulin. Thus, the UKPDS data do not support the suggestion of adverse cardiovascular effects from sulphonylureas. 
Exogenous
insulin has also been suggested as potentially harmful treatment because in-vitro studies with raised insulin concentrations induced atheroma,** and epidemiological studies showed an association between high plasma insulin concentrations and myocardial infarction.z5.*6 We did not find an increase in myocardial infarctions in patients assigned insulin therapy, even though their fasting plasma insulin concentrations were higher than those in any other group. The macrovascular subclinical surrogate endpoints did not differ between intensive and conventional groups, perhaps because 10 years' follow-up is too short to find changes in atheroma or because the endpoints were not sufficiently sensitive. Since there was no evidence, however, for a harmful cardiovascular effect of sulphonylurea or insulin therapy, it appears that the beneficial effect of an intensive glucose control with these agents outweighs the theoretical risks.
The 0.9% difference in HbA,, between the intensive (7.0%) and conventional (7.9%) groups over 10 years, an 11% reduction, is smaller than the 1.9% difference (9.0% and 7.1%; 20% reduction) in HbA,, in the DCCT. ' The DCCT studied younger patients with type 1 diabetes and used slightly different methods that focused on surrogate variables. The risk reductions seem proportional given the HbA,, differences: for progression of microvascular disease, 21% for retinopathy in UKFDS and 63% in the DCCT; and, for albuminuria, 34% and 54% respectively.' Our data suggest that clinical benefit can be obtained at lower HbA,, values than those in the DCCT.
Few patients had late ophthalmic complications such as vitreous haemorrhage or blindness and this may be because the follow-up was not long enough or, more likely, because of the decrease in retinal damage and blindness after photocoagulation.27 '28 The reduction in the progression of albuminuria by intensive treatment was probably accompanied by a reduced risk for development of renal failure, since there was a 67% risk reduction in the proportion of patients who had a two-fold increase in plasma creatinine and 74% risk reduction in those who had a doubling of their plasma urea. This result is potentially important since, although less than 1% of UKPDS patients developed renal failure, in many populations type 2 diabetes is the principal cause of renal failure.
No difference in the risk reduction of microvascular clinical endpoints was seen between the three intensive treatments, and thus, improved glycaemic control, rather than any one therapy, is the principal factor. Nevertheless, patients assigned chlorpropamide did not have the same risk reduction in progression of the retinopathy as those assigned glibenclamide or insulin, and this difference was not accounted for, statistically, by higher blood pressure in the chlorpropamide group. There was no difference in the progression of albuminuria between any treatment groups.
Increased blood pressure has been reported with chlorpropamide,29 which can also cause water retention.?" Other sulphonylureas that do not raise the blood pressure may be preferred.
Intensive blood-glucose control had disadvantages such as greater weight gain than occurred in the conventional group. There was also an increased risk of hypoglycaemic episodes, particularly in patients treated with insulin; each year about 3% had a major episode and 40% a minor or major hypoglycaemic episode. Although the increased risk of hypoglycaemia with insulin was less than that in the DCCT," this risk limited the extent to which normoglycaemia could be obtained in our patients with type 2 diabetes3z-as it does in patients with type 1 diabetes.*
The relation between glycaemia and outcome in our study is complex. Although a difference in HbA,, between conventional and intensive groups was maintained throughout, HbA,, progressively increased. The risks of hypoglycaemia and of weight gain, particularly in patients treated by insulin, are perceived by patients as difficulties that limit their ability to achieve improved glucose control (data not shown). Although early addition of other agents may have delayed the increasing hyperglycaemia, each of the available oral hypoglycaemic agents (sulphonylureas,33 metformin,3zs34 thiazolidinediones,'5 and acarboses6 have limited glucose-lowering efficacy and many patients eventually required insulin to avoid marked hyperglycaemia.
Our patients on intensive treatment with insulin achieved lower HbA,, values than those seen in several studies of intensive glucose control in patients with type 2 diabetes.37-39 Recent recommendationP set an HbA,, below 7% as a goal but, to our knowledge, this has been achieved only in intervention studies with high insulin doses, generally above 100 U per day, in small groups of obese patients who received detailed attention over a short period.",42 Studies of glycaemic control in type 2 diabetes with insulin therapy in the community report mean HbA,, values of 8~5%~~ and 9.0%.44 Current therapy of type 2 diabetes, including insulin regimens, may need to be reviewed. The US National Health and Nutrition Education Examination Survey III, by the same assay method as the DCCT, found that 5 1% of insulin-treated patients and 42% of those on oral hypoglycaemic agents had HbA,, values greater than 8%, (Maureen Harris, National Institute of Diabetes and Digestive and Kidney Diseases, USA, personal communication).
About 50% of patients with newly diagnosed type 2 diabetes already have diabetic tissue damage," but lack of benefit in these patients from early treatment has meant variation in the guidelines for screening populations.45~4" The UKPDS shows that improved blood-pressure47 and glucose control reduce the risk of the diabetic complications that cause both morbidity and premature mortality, and increase the case for formal screening programmes for early detection of diabetes in the general population.
Our study, despite the median of 10 years' follow-up is still short compared with the median life expectancy of 20 years in UKPDS patients diagnosed at median age 53 years. To investigate longer-term responses, we will carry out post-study monitoring of UKPDS for a further 5 years, to establish whether the improved glucose control achieved will substantially decrease the risk of fatal and non-fatal myocardial infarctions with longer follow-up. UKPDS shows that an intensive glucose-control treatment policy that maintains an 11% lower HbA,, ie, median 7.0% over the first 10 years after diagnosis of diabetes-substantially reduces the frequency of microvascular endpoints but not diabetes-related mortality or myocardial infarction. The disadvantages of intensive treatment are weight gain and risk of hypoglycaemia. There was no evidence that intensive treatment with chlorpropamide, glibenclamide, or insulin had a specific adverse effect on macrovascular disease. 
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